Theragen Etex Co., Ltd
KKRX:0667002,015.00
KRW
-5.00
(-0.25%)
ISIN
KR7066700006
Return %
Stock
S&P 500
1Y
-21.60
13.14
3Y
-47.66
80.78
5Y
-70.37
67.74
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- Full Time Employees
- 222
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Ansan-si South Korea
- IPO Date
- May 27, 2004
- Website
- theragenetex.com
- Similar Companies
- Business
- Theragen Etex Co., Ltd. is a South Korea-based healthcare and biotechnology group engaged in the development, manufacture, and distribution of finished pharmaceutical products, genomic diagnostic services, and innovative biopharmaceuticals. Founded in 1987 as Changho Pharm and headquartered in Seoul, South Korea, the company operates integrated business units spanning ethical pharmaceuticals, over-the-counter medications, next-generation sequencing diagnostics, bioinformatics platforms, and clinical-stage oncology therapeutics. The company's core operations are structured into several primary segments: Pharmaceutical Manufacturing and Marketing, which develops, produces, and commercializes a portfolio of over 200 prescription and generic medications across therapeutic areas such as cardiovascular and circulatory systems (including Clopidogrel and Rosuvastatin), gastrointestinal and digestive disorders, musculoskeletal conditions and pain management (including Loxoprofen-based non-steroidal anti-inflammatory formulations), endocrine and metabolic diseases (including Febuxostat for hyperuricemia and Ibandronate Sodium for osteoporosis), urological conditions (including Tamsulosin for benign prostatic hyperplasia), and respiratory ailments; Contract Development and Manufacturing Organization (CDMO) Services, providing formulation development, contract manufacturing, quality testing, and packaging compliant with PIC/S Good Manufacturing Practice (GMP) standards from its production complex in Ansan, South Korea; Genomics, Precision Medicine, and Bioinformatics, conducted primarily through its affiliate Theragen Bio, offering next-generation sequencing (NGS), whole-genome sequencing (WGS), whole-exome sequencing (WES), transcriptome RNA sequencing, clinical oncology profiling platforms (such as Oncomics and OncoTERA), direct-to-consumer (DTC) personalized health risk genetic testing (under brands including GeneStyle), and big data-driven bioinformatic analytics; Targeted Biopharmaceutical Research, managed through clinical-stage oncology affiliate MedPacto, focusing on novel therapeutics including Vactosertib, an oral TGF-beta receptor type 1 inhibitor under investigation for solid tumors, desmoid tumors, metastatic colorectal cancer, and pancreatic adenocarcinoma; and Specialized Healthcare Logistics and Diagnostics, provided through affiliates including GenomeCare for non-invasive prenatal testing (NIPT) and bioinformatic diagnostic software, alongside LeadPharm and Theragen Healthcare for pharmaceutical wholesale distribution and pharmacy network management. Theragen Etex supplies its pharmaceutical products to domestic hospitals, clinics, and pharmacy retail networks across South Korea, while its genomic sequencing, precision diagnostics, and bioinformatics services serve research institutions, medical centers, and biotechnology partners across more than 40 countries in Asia-Pacific, North America, and Europe. In recent developments, Theragen Etex has advanced strategic initiatives to expand its precision medicine footprint and enhance core pharmaceutical operational efficiencies. The group deepened digital health and personalized diagnostic alliances, including ongoing commercial collaboration with Lotte Healthcare via the specialized joint affiliate Theragen Health for tailored genetic nutrition solutions. In its oncology pipeline, clinical affiliate MedPacto advanced key clinical trials and regulatory designations for its lead candidate Vactosertib in combination therapies with global checkpoint inhibitors. Additionally, Theragen Etex has upgraded its Ansan manufacturing facility to scale production of higher-margin proprietary ethical pharmaceuticals, optimized its contract manufacturing business, and restructured affiliate holdings to reinforce financial stability and focus capital on core pharmaceutical sales, advanced genomic analytics, and targeted therapeutic development.